| Literature DB >> 26735845 |
Brechje de Gier1, Maiza Campos Ponce2, Marlene Perignon3, Marion Fiorentino3, Kuong Khov4, Chhoun Chamnan4, Michiel R de Boer5, Megan E Parker6, Kurt Burja7, Marjoleine A Dijkhuizen8, Jacques Berger3, Katja Polman2,9, Frank T Wieringa3.
Abstract
BACKGROUND: Fortification of staple foods is considered an effective and safe strategy to combat micronutrient deficiencies, thereby improving health. While improving micronutrient status might be expected to have positive effects on immunity, some studies have reported increases in infections or inflammation after iron supplementation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26735845 PMCID: PMC4703301 DOI: 10.1371/journal.pone.0145351
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Micronutrient composition of the three types of fortified rice.
N.I. = not included in premix
| Micronutrient | Target value(mg) | UltraRice _original(mg) | UltraRice _improved(mg) | NutriRice (mg) |
|---|---|---|---|---|
| 0.3 | N.I. | 0.64 | 0.29 | |
| 7.26 | 10.67 | 7.55 | 7.46 | |
| 3.5 | 3.0 | 2.0 | 3.7 | |
| 0.6 | 1.1 | 1.4 | 0.7 | |
| 8 | N.I. | 12 | 8 | |
| 0.65 | N.I. | N.I. | 0.92 | |
| 0.2 | 0.2 | 0.3 | 0.1 | |
| 0.001 | N.I. | 0.004 | 0.001 |
Fig 1Flow chart of the study.
Population characteristics at baseline.
| Placebo | UltraRice_original | UltraRice_improved | Nutririce | |
|---|---|---|---|---|
| 492 (49.9%) | 479 (49.6%) | 500 (49.8%) | 506 (50.8%) | |
| 9.58 ± 2.27 | 9.61 ± 2.19 | 9.64 ± 2.22 | 9.71 ± 2.42 | |
| 74/354 (20.9%) | 82/362 (22.7%) | 67/364 (18.4%) | 36/316 (11.5%) | |
| 8.0–37.6% | 0–48.1% | 5.1–33.3% | 4.8–26.9% | |
| 70 | 81 | 65 | 36 | |
| 4 | 1 | 2 | 0 | |
| 0 | 0 | 0 | 0 | |
| 124 | 117 | 123 | Na | |
| 22.7 (21.2 to 26.3) | 22.7 (20.2 to 26.9) | 21.7 (20.3 to 26.3) | Na | |
| 13 (10.5%) | 7 (6%) | 13 (10.6%) | Na |
Fig 2Effect of micronutrient-fortified rice consumption or placebo on hookworm infection.
Hookworm infection prevalence in all children (A, N = 1393) and baseline uninfected children (B, N = 1134) per study group, during the course of the intervention, with error bars depicting crude 95% confidence intervals for the proportion infected.
Longitudinal effects of micronutrient fortified rice on hookworm infection risk of baseline uninfected children.
| Hookworm infection: baseline uninfected children | |||||||
|---|---|---|---|---|---|---|---|
| Baseline n/N (%) | 3 months n/N (%) | 7 monthsn/N (%) | crude % point risk difference with placebo (95% CI) | aOR | 95% CI | P value | |
| Placebo | 0/280 (0.0) | 26/214 (12.1) | 23/194 (11.9) | 1 (ref) | |||
| Any fortified rice | 0/854 (0.0) | 97/576 (16.8) | 125/591 (21.2) | + 9.3% (2.9 to 14.7) | 1.86 | 1.17 to 2.95 | 0.009 |
| - UltraRice_ original | 0/280 (0.0) | 34/207 (16.4) | 56/228 (24.6) | + 12.7% (5.3 to 19.8) | 1.89 | 1.06 to 3.37 | 0.032 |
| - UltraRice_improved | 0/297 (0.0) | 39/208(18.8) | 41/188 (21.8) | + 10.0% (2.5 to 17.4) | 1.91 | 1.12 to 3.26 | 0.018 |
| - NutriRice | 0/277 (0.0) | 24/161 (14.9) | 28/175 (16.0) | + 4.1% (-2.9 to 11.4) | 1.74 | 0.63 to 4.81 | 0.284 |
1 From mixed modelanalysis, adjusted for sex, age (in quartiles) and baseline prevalence of hookworm at the school.
Effect of micronutrient fortified rice on hookworm infection risk of baseline uninfected children, stratified by baseline school hookworm prevalence.
| Hookworm infection risk by school prevalence category | ||||||
|---|---|---|---|---|---|---|
| Baseline prevalence < 15% | ||||||
| Baseline n/N (%) | 3 months n/N (%) | 7 months n/N (%) | aOR | 95% CI | P value | |
| Placebo | 0/92(0.0) | 15/82 (18.3) | 4/74 (5.4) | 1 (ref) | ||
| Any fortified rice | 0/477 (0.0) | 35/312 (11.2) | 44/311 (14.1) | 0.96 | 0.62 to 1.47 | 0.840 |
| - UltraRice_ original | 0/87(0.0) | 13/64 (20.3) | 19/69 (27.5) | 2.29 | 2.13 to 2.46 | <0.001 |
| - UltraRice_ improved | 0/162(0.0) | 11/116 (9.4) | 10/91 (10.9) | 0.82 | 0.49 to 1.37 | 0.454 |
| - NutriRice | 0/228(0.0) | 11/132 (8.3) | 15/151 (9.9) | 0.73 | 0.53 to 1.03 | 0.070 |
| Baseline prevalence >15% | ||||||
| Baseline n/N (%) | 3 months n/N (%) | 7 months n/N (%) | aOR | 95% CI | P value | |
| Placebo | 0/139(0.0) | 11/132 (8.3) | 19/120 (15.8) | 1 (ref) | ||
| Any fortified rice | 0/377 (0.0) | 62/264 (23.5) | 81/280 (28.9) | 2.94 | 1.82 to 4.77 | <0.001 |
| - UltraRice_ original | 0/193(0.0) | 21/143 (14.7) | 37/159 (26.3) | 1.82 | 1.33 to 2.49 | <0.001 |
| - UltraRice_ improved | 0/135(0.0) | 28/92 (30.4) | 31/97 (32.0) | 3.73 | 2.76 to 5.05 | <0.001 |
| - NutriRice | 0/49(0.0) | 13/29 (44.8) | 13/24 (54.2) | 8.65 | 6.59 to 11.34 | <0.001 |
1From mixed model analysis, adjusted for sex and age (in quartiles).
Effects of UltraRice_original and UltraRice_improved on prevalence of elevated fecal calprotectin (>50 mg/kg).
| Fecal calprotectin >50 mg/kg | |||||
|---|---|---|---|---|---|
| Baseline n/N (%) | 7 months n/N (%) | aOR | 95% CI | P value | |
| Placebo | 13/124 (10.5) | 39/101 (38.6) | 1 (ref) | ||
| Any fortified rice | 20/240 (8.3) | 78/243 (32.1) | 0.69 | 0.46 to 1.02 | 0.065 |
| - UltraRice_original | 7/117 (6.0) | 39/121 (32.2) | 0.74 | 0.32 to 1.72 | 0.481 |
| - UltraRice_improved | 13/123 (10.6) | 39/122 (32.0) | 0.66 | 0.29 to 1.51 | 0.324 |
1 From mixed model analyses, adjusted for sex, age (in quartiles), baseline calprotectin >50 mg/kg yes/no, N = 330